Scinai Immunotherapeutics Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
CDMO Revenue Annually1.3M
CDMO Unit Breakeven Timeline AnnuallyTarget: Breakeven by end of 2026
Watch Items
- Integration of Yavne CDMO Facility (formerly Recipharm Israel)Trigger: Operational disruption or failure to meet the $5 million 2026 revenue targetAction: Re-evaluate CDMO capacity utilization and commercial collaboration with Recipharm AB
- Nasdaq Minimum Bid Price ComplianceTrigger: Bid price remains below $1.00 per shareAction: Monitor closing bid price and consider implementing a reverse stock split or other capital restructuring options
- PC111 Flagship Program FundingTrigger: Rejection of FENG grant applications or failure to secure non-dilutive fundingAction: Assess alternative clinical development approaches or seek dilutive private placements
Research as of 20 Jun 2026